Csl (QX) Stock Quote CSLLY - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

88.18

Bid

87.42

Ask

89.24

Volume

64,364

85.26 Day's Range 89.83

83.31 52 Week Range 109.00

Market Cap

85.226B

Previous Close

87.88

Open

85.26

Last Trade

100

88.18

Last Trade Time

Financial Volume

$ 5,683,653

VWAP

88.3048

Average Volume (3m)

64,398

Shares Outstanding

966,505,458

Dividend Yield

PE Ratio

103.00

Earnings Per Share (EPS)

2.73

Revenue

14.69B

Net Profit

2.64B

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.csl.com.au

Headquarters

Melbourne, Victoria, Aus

Founded

1916

Csl Ltd (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker CSLLY. The last closing price for Csl (QX) was $87.88. Over the last year, Csl (QX) shares have traded in a share price range of $ 83.31 to $ 109.00.

Csl (QX) currently has 966,505,458 shares outstanding. The market capitalization of Csl (QX) is $84.94 billion. Csl (QX) has a price to earnings ratio (PE ratio) of 103.00.

Form 3 - Initial statement of beneficial ownership of securities

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for Neurological Disorders PR Newswire KING OF PRUSSIA, Pa...

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO, June 24, 2015 - Data supports prolonged dosing...

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24, 2015 Data Presented during Late Breaking Session at...

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how value of biopharmaceutical technologies is assessed...

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More than 20 abstracts focusing on investigational and...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) PR Newswire KING OF...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.295	-0.333427521899	88.475	90.03	85.26	93218	88.21522852	DR
4	-5.57	-5.94133333333	93.75	93.75	83.31	69993	88.63747892	DR
12	-9.7985	-10.0006634109	97.9785	101.44	83.31	64398	90.5291194	DR
26	-11.33	-11.3857903728	99.51	109	83.31	40386	93.40556268	DR
52	-7.29	-7.63590656751	95.47	109	83.31	38062	93.52931237	DR
156	-18.31	-17.1941027327	106.49	110.25	71.51	65613	91.85336949	DR
260	-10.5225	-10.6608241939	98.7025	117.98	71.51	58093	95.80870622	DR

CSLLY - Frequently Asked Questions (FAQ)

What is the current Csl (QX) share price?

The current share price of Csl (QX) is $ 88.18

How many Csl (QX) shares are in issue?

Csl (QX) has 966,505,458 shares in issue

What is the market cap of Csl (QX)?

The market capitalisation of Csl (QX) is USD 84.94B

What is the 1 year trading range for Csl (QX) share price?

Csl (QX) has traded in the range of $ 83.31 to $ 109.00 during the past year

What is the PE ratio of Csl (QX)?

The price to earnings ratio of Csl (QX) is 103

What is the cash to sales ratio of Csl (QX)?

The cash to sales ratio of Csl (QX) is 18.52

What is the reporting currency for Csl (QX)?

Csl (QX) reports financial results in USD

What is the latest annual turnover for Csl (QX)?

The latest annual turnover of Csl (QX) is USD 14.69B

What is the latest annual profit for Csl (QX)?

The latest annual profit of Csl (QX) is USD 2.64B

What is the registered address of Csl (QX)?

The registered address for Csl (QX) is 45 POPLAR ROAD, PARKVILLE, MELBOURNE, VICTORIA, 3052

What is the Csl (QX) website address?

The website address for Csl (QX) is www.csl.com.au

Which industry sector does Csl (QX) operate in?

Csl (QX) operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GNSPFGenusPlus Group Ltd (PK)	$ 1.60 (319,900.00%)	1,000
UNDRUnderSea Recovery Corporation (CE)	$ 0.0009 (89,900.00%)	25k
ERHEERHC Energy Inc (CE)	$ 0.0003 (29,900.00%)	211
SVSNStereo Vision Entertainment Inc (CE)	$ 0.0002 (19,900.00%)	500
CLVRClever Leaves Holdings Inc (CE)	$ 0.025 (12,400.00%)	1.76k
MEDEMEdIES (CE)	$ 0.000001 (-100.00%)	2.84k
EWGFFEat Well Investment Group Inc (CE)	$ 0.000001 (-100.00%)	17.4k
EHVVFEhave Inc (CE)	$ 0.000001 (-99.90%)	336.51k
NEPTFNeptune Wellness Solutions Inc (CE)	$ 0.000001 (-99.90%)	40.53k
HREEFStans Energy Corp (CE)	$ 0.000001 (-99.90%)	2.5k
RONNRonn Motor Group Inc (PK)	$ 0.0006 (50.00%)	490.93M
GRLFGreen Leaf Innovations Inc (PK)	$ 0.0001 (0.00%)	374.74M
PHILPHI Group Inc (PK)	$ 0.0005 (0.00%)	368.3M
HMBLHUMBL Inc (PK)	$ 0.0009 (5.88%)	209.25M
GTCHGBT Technologies Inc (PK)	$ 0.00015 (-25.00%)	184.78M